CRISPR Therapeutics AG (NASDAQ:CRSP) Director Bradley J. Phd Bolzon sold 30,374 shares of the business's stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $132.37, for a total value of $4,020,606.38. Following the completion of the transaction, the director now owns 57,149 shares in the company, valued at approximately $7,564,813.13. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ:CRSP traded down $10.94 during trading on Wednesday, hitting $115.55. 2,177,762 shares of the stock were exchanged, compared to its average volume of 2,414,115. The company has a fifty day moving average price of $141.04 and a two-hundred day moving average price of $129.64. The company has a market cap of $8.72 billion, a PE ratio of -35.66 and a beta of 2.37. CRISPR Therapeutics AG has a 12-month low of $38.10 and a 12-month high of $220.20.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, February 15th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.23). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. The company had revenue of $0.37 million during the quarter, compared to analysts' expectations of $4.69 million. As a group, research analysts predict that CRISPR Therapeutics AG will post -4.97 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Nikko Asset Management Americas Inc. lifted its stake in CRISPR Therapeutics by 3.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,836,823 shares of the company's stock valued at $587,456,000 after buying an additional 139,156 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in CRISPR Therapeutics by 8.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,774,436 shares of the company's stock valued at $271,684,000 after buying an additional 143,504 shares in the last quarter. BlackRock Inc. lifted its stake in CRISPR Therapeutics by 1.7% in the 4th quarter. BlackRock Inc. now owns 1,173,259 shares of the company's stock valued at $179,640,000 after buying an additional 19,416 shares in the last quarter. Morgan Stanley lifted its stake in shares of CRISPR Therapeutics by 45.3% during the 4th quarter. Morgan Stanley now owns 731,427 shares of the company's stock worth $111,988,000 after purchasing an additional 227,927 shares during the period. Finally, Norges Bank purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $86,215,000. 66.43% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on the company. JMP Securities assumed coverage on CRISPR Therapeutics in a research report on Wednesday, March 10th. They issued an "outperform" rating and a $160.00 price target on the stock. Wells Fargo & Company cut CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $102.63 to $145.00 in a research report on Monday, December 7th. Piper Sandler boosted their target price on CRISPR Therapeutics from $107.00 to $180.00 and gave the stock an "overweight" rating in a research report on Thursday, December 10th. Truist boosted their target price on CRISPR Therapeutics from $170.00 to $210.00 in a research report on Tuesday, January 12th. Finally, TheStreet cut CRISPR Therapeutics from a "c-" rating to a "d" rating in a research report on Wednesday, March 10th. Three analysts have rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of "Hold" and a consensus target price of $159.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Featured Story: Trading Halts Explained

Insider Buying and Selling by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Stocks It May Be Time To Take Profits On

Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.

Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.

Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.

View the "7 Stocks It May Be Time To Take Profits On".



Source link